宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

未开盘 06-05 16:09:10

21.600

-0.960

-4.26%

最高24.680	最低21.540	成交量423.19万
今开24.400	昨收22.560	日振幅13.92%
总市值70.41亿	流通市值33.26亿	总股本3.26亿
成交额9,891万	换手率2.75%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":21.6,"timestamp":1780646950792,"preClose":22.56,"halted":0,"volume":4231900,"delay":0,"changeRate":-0.04255319148936158,"floatShares":154000000,"shares":325981465,"eps":-1.5689209579993888,"marketStatus":"未开盘","change":-0.96,"latestTime":"06-05 16:09:10","open":24.4,"high":24.68,"low":21.54,"amount":98912647,"amplitude":0.139184,"askPrice":21.84,"askSize":400,"bidPrice":21.6,"bidSize":12900,"shortable":0,"etf":0,"ttmEps":-1.5493094460243964,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":0,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":22.56,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":1.31441549061558,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"1195643371","title":"异动解读｜宝济药业-B盘中上涨5.59%，核心管线KJ103上市申请获受理叠加生物科技板块回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1195643371","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195643371?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:41","pubTimestamp":1780623718,"startTime":"0","endTime":"0","summary":"6月5日，宝济药业-B盘中上涨5.59%，报23.94港元/股，成交额1727.3万港元。消息面上，公司6月4日公告自主研发的注射用KJ103新药上市许可申请获国家药品监督管理局受理，用于高度致敏肾移植患者脱敏治疗，并已于5月20日获纳入优先审评程序。KJ103为全球首创低免疫原性IgG降解酶，III期临床数据显示移植前脱敏成功率及肾脏移植成功率均达100%。此外，生物科技板块今日整体回暖，科伦博泰生物涨6.87%、信达生物涨2.94%、康方生物涨1.76%，行业情绪修复提振个股表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815529","title":"宝济药业-B(02659)：注射用KJ103上市许可申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815529","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640815529?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:29","pubTimestamp":1780565343,"startTime":"0","endTime":"0","summary":"于2024年11月19日该适应症被NMPA药品审评中心批准纳入突破性治疗认定。KJ103目前已完成III期临床试验所有入组受试者的主要试验随访，已完成的临床试验可支持该产品的上市许可申请。KJ103给药后可迅速有效地降低或消除HLA 抗体，于移植前实现100%的脱敏治疗成功率和100%的肾脏移植成功率，3个月以上移植物存活率为100%。此外，本公司也在积极探索KJ103在其他抗体介导的急性自身免疫性疾病的治疗潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163397983","title":"异动解读｜宝济药业-B盘中上涨13.37%，超跌反弹叠加多重利好催化修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1163397983","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163397983?lang=zh_cn&edition=full","pubTime":"2026-06-04 13:12","pubTimestamp":1780549929,"startTime":"0","endTime":"0","summary":"6月4日，宝济药业-B盘中上涨13.37%，报23.98港元/股，成交额3794.29万港元。消息面上，公司此前连续两个交易日跟随生物科技板块系统性走弱分别下跌5.46%及5.3%，股价触及52周新低22.90港元后出现强势反弹。此外，公司已被纳入MSCI全球指数，前期被动资金调仓抛压消化后，市场信心进入修复阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122877857","title":"异动解读｜宝济药业-B盘中下跌5.3%，生物科技板块系统性走弱延续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1122877857","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122877857?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:52","pubTimestamp":1780386730,"startTime":"0","endTime":"0","summary":"6月2日，宝济药业-B盘中下跌5.3%，报21.82港元/股，成交额3912.25万港元。消息面上，生物科技板块今日延续系统性走弱态势，行业个股普遍承压，其中三生制药跌8.8%、康方生物跌8.28%、科伦博泰生物跌7.35%、信达生物跌2.6%、百济神州跌1.52%，板块整体抛压显著。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长刘彦君落定、中邮证券首予\"增持\"评级、获纳入MSCI全球指数等多重利好催化，但市场信心仍处于修复阶段，在行业系统性回调背景下个股跟随走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127894406","title":"宝济药业-B公布2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127894406","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127894406?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:08","pubTimestamp":1780304924,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年6月1日发布2026年5月的证券变动月报表。报告显示，截至5月31日，公司各类已发行股份总体数量保持不变，未进行任何新增发行、购回或注销行为，股本结构稳定。公司本月底法定/注册股本总额为65,196,293元人民币。公告由公司执行董事刘彦君签署，并重申公司遵守香港联交所《上市规则》及其他相关法律规定。根据公告信息显示，公司目前股本维持不变，符合相关监管要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117543784","title":"异动解读｜宝济药业-B盘中下跌5.46%，MSCI纳入生效首日遭抛压叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1117543784","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117543784?lang=zh_cn&edition=full","pubTime":"2026-06-01 14:36","pubTimestamp":1780295769,"startTime":"0","endTime":"0","summary":"6月1日，宝济药业-B盘中下跌5.46%，报23.2港元/股，成交额4265.7万港元。消息面上，公司此前获纳入MSCI全球指数成分股，于5月29日收市后正式生效，今日为生效后首个交易日。此外，生物科技板块今日整体承压，百济神州跌3.45%、科伦博泰生物跌6.8%、信达生物跌2.88%，行业系统性走弱加剧个股回调。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长落定、中邮证券首予\"增持\"评级，但市场信心仍处于修复阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933019","title":"【券商聚焦】中邮证券首予宝济药业-B(02659)“增持”评级 指公司商业化元年开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933019","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640933019?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:55","pubTimestamp":1780293315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，2025年宝济药业-B 实现总收入4916万元，较2024年的616万元大幅增长，主要得益于4000万元许可收入及首款商业化产品SJ02（晟诺娃）的364万元净收入。年内亏损3.95亿元，亏损同比扩大主要受计提5510万元诉讼拨备等非经营性因素影响。业务层面，首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司进入商业化阶段。核心产品重组人透明质酸酶KJ017于2026年3月31日获批，系国内首款获批产品。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639642125","title":"中邮证券：首予宝济药业-B(02659)“增持”评级 平台价值逐步兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2639642125","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639642125?lang=zh_cn&edition=full","pubTime":"2026-05-29 14:07","pubTimestamp":1780034864,"startTime":"0","endTime":"0","summary":"公司首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司正式进入商业化阶段。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129712989","title":"异动解读｜宝济药业-B盘中上涨5.05%，新任董事长落定叠加管线利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1129712989","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129712989?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:50","pubTimestamp":1779864600,"startTime":"0","endTime":"0","summary":"5月27日，宝济药业-B盘中上涨5.05%，报26.24港元/股，成交额8176.22万港元。消息面上，公司于5月26日公告，刘彦君博士获委任为第二届董事会董事长，任期三年。此外，近期公司核心管线注射用KJ103拟纳入优先审评，该产品为全球首创的重组IgG降解酶，适用于高度致敏肾移植患者脱敏治疗。此前公司股价自4月底闪崩暴跌65%后持续低位运行，控股股东已表态拟增持股份，新管理层架构确立叠加研发管线推进，市场情绪有所修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510008","title":"宝济药业-B(02659)：刘彦君获委任为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638510008?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:58","pubTimestamp":1779803887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，刘彦君博士、王征女士及李翠女士获重选为第二届董事会执行董事;林佳陵女士、刁隽桓先生及LiChen先生获重选为第二届董事会非执行董事;及蔡仲曦先生、曾凡一博士、鞠佃文博士及张森泉先生获重选为第二届董事会独立非执行董事。于紧随股东周年大会后举行的第二届董事会第一次会议上，刘彦君博士获委任为第二届董事会董事长，任期自2026年5月26日起至第二届董事会任期届满之日止为期三年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111545287","title":"异动解读｜宝济药业-B盘中下跌5.02%，报25.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111545287","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111545287?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:35","pubTimestamp":1779330952,"startTime":"0","endTime":"0","summary":"5月21日，宝济药业-B盘中下跌5.02%，报25.36港元/股，成交额3535.91万港元。宝济药业-B所在的生物科技行业中，板块整体表现偏强，个股中，康方生物涨5.91%，荣昌生物涨4.31%，信达生物涨2.96%，百济神州涨1.93%，三生制药涨0.36%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131609185","title":"异动解读 | 获纳入MSCI指数及多重利好提振，宝济药业-B盘中大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131609185","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131609185?lang=zh_cn&edition=full","pubTime":"2026-05-19 10:27","pubTimestamp":1779157646,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨5.80%，市场表现强劲。消息面上，公司此前宣布成功被纳入MSCI全球小型股指数成分股，相关调整将于5月底收市后正式生效。此次纳入有望为公司股票带来增量被动资金配置，提升市场流动性与国际知名度。此外，公司控股股东刘彦君博士此前宣布的增持计划仍在执行期内，叠加核心产品注射用KJ103拟纳入优先审评等多重利好因素，共同为股价提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636028276","title":"港股异动 | 宝济药业-B(02659)最高涨超23% 获纳入MSCI全球指数成分股 将于5月29日收市后生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2636028276","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636028276?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:52","pubTimestamp":1779090762,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B尾盘最高涨超23%，截至发稿，涨6.22%，报26.66港元，成交额3.61亿港元。消息面上，宝济药业近日宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1691799644.USD","LU2095319765.USD","LU2210150020.SGD","LU1267930730.SGD","LU0320765059.SGD","LU0175139822.USD","LU0289960550.SGD","LU2265009873.SGD","BK4588","MSCI","LU0390134368.USD","IE00BKPKM429.USD","LU0708995401.HKD","BK4112","VXUS","LU1804176565.USD","LU0289961442.SGD","LU0511384066.AUD","BK4585","02659","BK1161","LU2210149790.SGD","LU0289739343.SGD","LU0109391861.USD","LU0672654240.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147308433","title":"异动解读 | 入选夏季路演大会名单，宝济药业-B盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147308433","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147308433?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:18","pubTimestamp":1779088702,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅上涨5.18%，引起了市场的关注。消息面上，智通财经宣布将于5月28日举办“2026智通财经夏季路演大会”，旨在搭建上市公司与投资者之间的沟通桥梁。在已公布的部分路演上市公司名单中，宝济药业-B位列其中。市场分析认为，公司参与此类重要资本市场活动，有助于提升其在投资者群体中的能见度，并可能被视为积极与市场沟通、寻求价值认可的举措，从而提振了股价。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164039178","title":"异动解读 | 生物科技板块整体承压，宝济药业-B盘中大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164039178","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164039178?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:49","pubTimestamp":1779072570,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价出现大幅下挫，跌幅达5.26%。消息面上，此次下跌主要受其所在的生物科技行业板块整体表现疲软拖累。板块内多数个股均呈现下跌态势，市场情绪偏向谨慎。同板块中，信达生物、康方生物、科伦博泰生物、百济神州及荣昌生物等个股亦同步走低，显示出板块整体承压的态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09696","02706","02411","02228","01907","01300","06682","02670","06636","02575","06090","00305","02659","LU0307460666.USD","02565","02652","06938","LU0287142896.SGD","01333","BK1100","HK0001040143.USD","06651","02526","08299","02726","00826","03858","LU0314109678.HKD","02729","02889","02675","01021","BK1171","VXUS","02685","03881","01396","00363","BK1155","01378","06051","02142","03317","02623","02650","00290","01384","02655","00400","00650"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635676392","title":"宝济药业(02659)获纳入MSCI全球指数成分股 创新研发实力获得全球认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2635676392","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635676392?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:54","pubTimestamp":1778723663,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年5月14日，宝济药业宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。此次被纳入该指数，标志着宝济药业在全球资本市场的知名度和影响力进一步提升，将有助于公司股票获得更广泛的国际投资者关注，带来增量被动资金的潜在配置，并进一步提升股份的市场流动性、交易活跃度及国际知名度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0672654240.SGD","LU0289739343.SGD","LU0289961442.SGD","IE00BKPKM429.USD","BK4588","LU0511384066.AUD","LU0390134368.USD","LU1804176565.USD","LU0109391861.USD","LU2095319765.USD","LU0708995401.HKD","LU0289960550.SGD","LU2210149790.SGD","02659","MSCI","LU1267930730.SGD","LU1691799644.USD","BK1161","BK4585","LU2210150020.SGD","LU0320765059.SGD","LU2265009873.SGD","BK4112","LU0175139822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103794009","title":"异动解读 | 控股股东拟增持叠加新品获批，宝济药业-B盘中大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103794009","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103794009?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:07","pubTimestamp":1778638055,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，此次股价上涨主要受到两大利好因素的推动。首先，公司董事会主席兼控股股东刘彦君博士宣布，计划在三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举向市场释放了控股股东对公司长期价值坚定认可的积极信号。控股股东的增持意愿与核心新产品的成功获批形成合力，共同提振了市场信心，推动了股价的强势表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635220997","title":"港股异动 | 宝济药业-B(02659)早盘涨超7% 注射用KJ103拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2635220997","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635220997?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:07","pubTimestamp":1778638033,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B(02659)早盘涨超7%，截至发稿，涨6.99%，报29.4港元，成交额8606.39万港元。消息面上，5月12日，CDE官网显示，宝济药业注射用KJ103拟纳入优先审评，适用于高度致敏的肾移植患者进行脱敏治疗，有效清除预存HLA抗体预防超急性排斥反应。据介绍，KJ103是一款全球首创、低免疫原性的重组免疫球蛋白G(IgG)降解酶，用于治疗由病理性IgG抗体介导的多种免疫性疾病。该产品通过特异性切割并降解血液循环中的病理性IgG抗体，抑制免疫应答激活，为抗体介导的自身免疫性疾病提供了靶向、快速的治疗新选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","VXUS","BK4585","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147725778","title":"异动解读 | 宝济药业-B盘中大涨5.62%，控股股东增持计划及新品获批提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1147725778","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147725778?lang=zh_cn&edition=full","pubTime":"2026-05-11 09:49","pubTimestamp":1778464170,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨5.62%，引起了投资者的广泛关注。消息面上，公司董事会主席兼控股股东集团成员刘彦君博士此前宣布，拟于三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举持续向市场释放了对公司长期价值的认可信号。同时，公司的注射用人玻璃酸酶已获国家药监局批准上市，为产品管线再添商业化品种，增强了未来的盈利预期。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":-0.1198},{"period":"1month","weight":-0.129},{"period":"3month","weight":-0.787},{"period":"6month","weight":-0.1812},{"period":"ytd","weight":-0.7215}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}